Insider · CIK 0001269341

VINCENT RICHARD G

Reports to the SEC for 4 companies · DALLAS, TX

sec.gov

Transactions

Companies

Filings

CIK

0001269341

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−2,000 sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−31K sh	—	—	0
2026-08-27	FBRXForte Biosciences, Inc. · Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−18.4K sh	—	—	0
2026-05-29	FBRXForte Biosciences, Inc. · Restricted Stock UnitsA Award	Director	AAward	+18.4K sh	—	—	18,353
2025-03-20	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+31K sh	—	—	31,000
2024-09-17	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+2,000 sh	—	—	2,000
2024-02-14	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+14.2K sh	—	—	14,200
2024-01-03	Oncternal Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−8,868 sh	$0.50	−$4,399.415	140,922
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−75K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−35.1K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−280K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−110K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−28.8K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−210K sh	—	—	0
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+35.1K sh	—	—	35,120
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+280K sh	—	—	280,000
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+110K sh	—	—	109,597
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+28.8K sh	—	—	28,750
2023-10-02	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+210K sh	—	—	210,000
2023-07-03	Oncternal Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−7,069 sh	$0.36	−$2,544.84	149,790
2023-04-13	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+30K sh	$0.30	+$8,961	156,859
2023-02-21	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+210K sh	—	—	210,000
2023-01-03	Oncternal Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−4,428 sh	$1.02	−$4,516.56	126,859
2022-07-28	Oncternal Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+43.1K sh	—	—	131,287
2022-07-28	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+28.8K sh	—	—	28,750
2022-03-28	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,500 sh	$1.40	+$3,500	88,162
2022-03-25	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+356 sh	$1.45	+$516.2	83,521
2022-03-25	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5 sh	$1.48	+$7.4	83,526
2022-03-25	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,136 sh	$1.49	+$3,182.426	85,662
2022-03-24	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+3 sh	$1.45	+$4.35	83,165
2022-01-28	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,500 sh	$1.65	+$4,125	83,162
2022-01-27	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$1.80	+$9,000	75,662
2022-01-27	Oncternal Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+5,000 sh	$1.70	+$8,500	80,662
2022-01-20	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+110K sh	—	—	109,579
2022-01-03	Oncternal Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+29.9K sh	—	—	70,662
2021-02-11	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+280K sh	—	—	280,000
2020-03-17	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	−35.1K sh	—	—	35,120
2020-03-17	Oncternal Therapeutics, Inc.Common StockA Award	Chief Financial Officer	AAward	+35.1K sh	—	—	35,120
2019-09-12	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2019-09-12	Oncternal Therapeutics, Inc.Stock OptionA Award	Chief Financial Officer	AAward	−75K sh	—	—	75,000
2019-06-07	Oncternal Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+42.6K sh	—	—	40,794
2019-06-07	Oncternal Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+4,526 sh	—	—	4,526
2019-06-07	Oncternal Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+1,834 sh	—	—	1,834
2019-06-07	Oncternal Therapeutics, Inc.Stock OptionsA Award	Chief Financial Officer	AAward	+73.4K sh	—	—	73,385
2019-06-07	Oncternal Therapeutics, Inc.WarrantsA Award	Chief Financial Officer	AAward	+281 sh	—	—	281
2014-10-07	Sorrento Therapeutics, Inc.Stock OptionsA Award	See Remarks	AAward	+50K sh	—	—	270,000
2013-10-29	Sorrento Therapeutics, Inc.Stock OptionsA Award	See Remarks	AAward	+100K sh	—	—	220,000
2012-09-30	Sorrento Therapeutics, Inc.Non-qualified stock optionD Disposition to Issuer	See Remarks	DDisposition to Issuer	−725K sh	—	—	2,275,000
2012-09-30	Sorrento Therapeutics, Inc.Non-qualified stock optionD Disposition to Issuer	See Remarks	DDisposition to Issuer	−725K sh	—	—	2,275,000

Recent filings

Accepted (ET)
Aug 274
VINCENT RICHARD G0001269341-26-000003
SEC(opens sec.gov)
Jun 24
VINCENT RICHARD G0001269341-26-000002
SEC(opens sec.gov)
Mar 214
VINCENT RICHARD G0001415889-25-008784
SEC(opens sec.gov)
Sep 194
VINCENT RICHARD G0001415889-24-023723
SEC(opens sec.gov)
Feb 154
VINCENT RICHARD G0001209191-24-003408
SEC(opens sec.gov)
Jan 54
VINCENT RICHARD G0001209191-24-000972
SEC(opens sec.gov)
Oct 44
VINCENT RICHARD G0001209191-23-052015
SEC(opens sec.gov)

Companies

Address

C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BUILDING 6

DALLAS, TX, 75247